Biotech entity
pharma is the sole category represented across all 2 tracked stories. AbbVie is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 34-day window averages about 0.4 stories each week. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. AbbVie is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 34-day window averages about 0.4 stories each week. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline. The average consequence score is 6, matching the 6 beat baseline for this window. BIMZELX appears in 2 tracked Biotech stories published from February 19, 2026 through March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 439 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BIMZELX. Shared-story counts are live from our verified record — not editorial picks.
Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios.
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
Source: weeklyvoice.com · admin (in)
BIMZELX is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
